Abstract:
A process to remove bad odours from plastic materials is disclosed, wherein said materials contain at least a polymer and at least a plasticiser. According to the process, natural or synthetic mono-, linear, branched or cyclic oligomeric carbohydrates are added during the compounding of the plastic formulation in order to fulfill the above indicated aim. The process is particularly suitable when said polymer is a polyvinyl chloride resin (PVC), chosen so as to exhibit a K value in the range K50-K85, and preferably in the range K64-K80. The invention also relates to a plastic material, containing at least a polymer and at least a plasticiser, on which natural or synthetic, mono-, linear, branched or cyclic oligomeric carbohydrates are grafted, once the formulation compounding already happened.
Abstract:
Disclosed herein are nanocarriers that include one or more cyclodextrin moieties conjugated to a polymer. The cyclodextrin moieties can complex therapeutic (e.g., anticancer) agents, and can be used to treat diseases such as cancer.
Abstract:
L'invention a pour objet une méthode de purification d'un polyrotaxane à base de cyclodextrines comprenant à titre d'impuretés des cyclodextrines libres, qui comprend les étapes suivantes : a) traitement thermique à une température allant de 70 à 300°C du polyrotaxane à base de cyclodextrines comprenant à titre d'impuretés des cyclodextrines libres, puis b) mise en solution du produit obtenu à l'étape a) dans un solvant dans lequel le polyrotaxane à base de cyclodextrines comprenant à titre d'impuretés des cyclodextrines libres est soluble avant le traitement thermique, puis c) une étape éventuelle de sonication au moyen d'ultrasons de la solution obtenue à l'étape b), puis d) élimination des constituants insolubles de la solution obtenue à l'étape c), e) séchage éventuel de la solution obtenue à l'étape d).
Abstract:
The present invention discloses a process for preparation of white curcumin from purified curcuminoids. The curcuminoids are obtained by solvent extraction and crystallization of dried turmeric powder. The autoclave is charged with ethyl acetate and the 95% purity curcuminoids mixture is added to and stirred for uniformity at room temperature. 5% (w/w) of 10% palladium carbon is added to the reaction mixture and allowed for hydrogenation in the presence of hydrogen gas at 2 lbps pressure and stirred continuously for 15 hours. Once the reaction is completed, the reaction mixture is filtered and washed with ethyl acetate. The ethyl acetate is distilled off and crude mass is stirred with water to obtain a solid precipitate. Finally, the solid obtained is filtered and dried to pale brown crystals of white curcumin. White curcumin is encapsulated with beta- cyclodextrin, which exhibited increased bioavailability. White curcumin also exhibited anti-oxidant and chemopreventive activities.
Abstract:
The present invention relates to a pharmaceutical composition comprising an inclusion complex of amorphous lenalidomide, or a pharmaceutically acceptable salt thereof, in non-substituted β-cyclodextrin and one or more pharmaceutically acceptable excipients. The invention further relates to the use of said composition as a medicament, particularly in the treatment of in the treatment of multiple myeloma and myelodyplastic syndromes.
Abstract:
The present invention relates to novel and useful pharmaceutical compositions formulated with a cyclodextrin compound and a budesonide derivative for the treatment and/or prevention of pulmonary inflammatory disease. The present invention also relates to a novel and useful analytical technique for the detection and the quantification of ΗΡ-β-CD in solution. More specifically, the present invention relates to the use of a validated 1H NMR analysis for the detection and quantification of cyclodextrins directly in pharmaceutical formulations without any extraction or separation steps for liquid formulations.
Abstract:
A hydrogel product comprising (a) one or more cyclodextrin molecules grafted to hyaluronic acid and (b) dextran, wherein the cyclodextrin-grafted hyaluronic acid is cross-linked to the dextran. The one or more cyclodextrin molecules are grafted, e.g. by amide bonds, to the hyaluronic acid prior to the cross- linking with dextran.
Abstract:
The present application provides polyanionic and non-ionic cyclodextrin-based compounds, and methods of manufacturing them. The compounds comprise a negatively-charged or neutral moiety (and, for polyanionic compounds, a suitable counter cation), one or more linkers, optionally one or more bridging groups, a cyclodextrin, and one or more substituents on the cyclodextrin. The compounds can be used in pharmaceutical compositions, and as excipients or carriers of guest molecules.
Abstract:
In one aspect, the disclosure features, a method of treating a cancer, e.g. colorectal cancer, e.g., rectal cancer, in a subject with a cyclodextrin containing polymer ("CDP") - camptothecin conjugate, particle or composition or camptothecin derivative conjugate, particle or composition described herein, e.g., CRLX101. The method comprises: providing an initial administration of a CDP-camptothecin conjugate, particle or composition or camptothecin derivative conjugate, particle or composition described herein, e.g., CRLX101.